TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Relay Therapeutics
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025

Relay Therapeutics presented subset analysis data for zovegalisib, a PI3Kα inhibitor, showing promising efficacy in breast cancer patients with various treatment histories, including 10.3-month median progression-free survival across patient groups.

Insights
RLAY   positive

Reported promising clinical trial results with consistent efficacy across different patient subgroups, demonstrating potential therapeutic value of their drug candidate zovegalisib